Is Acrivon Therapeutics, Inc. Common Stock (ACRV) overvalued? · $65.1M cap
Acrivon Therapeutics, Inc. Common Stock (ACRV) is a biotechnology company listed on NASDAQ.
This page asks whether Acrivon Therapeutics, Inc. Common Stock (ACRV) looks expensive on cached numbers — not a short thesis.
No cached income statement for ACRV, so there is no earnings base to call rich or cheap.
ACRV currently screens at market cap $65.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ACRV 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ACRV stock page for the full model, not this heading.
Not investment advice.